Symbols / CNTB
CNTB Chart
About
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 140.88M |
| Enterprise Value | 82.96M | Income | -49.28M | Sales | 762.00K |
| Book/sh | 0.99 | Cash/sh | 0.98 | Dividend Yield | — |
| Payout | 0.00% | Employees | 62 | IPO | — |
| P/E | — | Forward P/E | -2.73 | PEG | — |
| P/S | 184.88 | P/B | 2.54 | P/C | — |
| EV/EBITDA | -1.52 | EV/Sales | 108.88 | Quick Ratio | 4.81 |
| Current Ratio | 5.48 | Debt/Eq | 1.41 | LT Debt/Eq | — |
| EPS (ttm) | -0.89 | EPS next Y | -0.92 | EPS Growth | — |
| Revenue Growth | -98.70% | Earnings | 2025-11-12 09:00 | ROA | -38.67% |
| ROE | -66.80% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -1104.81% | Profit Margin | 0.00% | Shs Outstand | 55.90M |
| Shs Float | 12.77M | Short Float | 0.80% | Short Ratio | 3.48 |
| Short Interest | — | 52W High | 3.28 | 52W Low | 0.51 |
| Beta | -0.18 | Avg Volume | 159.06K | Volume | 31.56K |
| Target Price | $7.90 | Recom | None | Prev Close | $2.45 |
| Price | $2.52 | Change | 2.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.90
Mean price target
2. Current target
$2.45
Latest analyst target
3. DCF / Fair value
$-8.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.45
Low
$6.00
High
$10.00
Mean
$7.90
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-01 | init | Lake Street | — → Buy | $9 |
| 2025-11-13 | reit | BTIG | Buy → Buy | $10 |
| 2025-10-31 | init | BTIG | — → Buy | $10 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-13 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-04-17 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-03-04 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2023-09-13 | reit | Cantor Fitzgerald | Overweight → Overweight | $5 |
| 2023-02-08 | main | SVB Leerink | — → Outperform | $7 |
| 2022-06-02 | init | Cantor Fitzgerald | — → Overweight | $5 |
| 2022-05-05 | down | Piper Sandler | Overweight → Neutral | $2 |
| 2022-05-04 | main | SVB Leerink | — → Outperform | $9 |
| 2022-01-06 | main | SVB Leerink | — → Outperform | $22 |
| 2021-04-13 | init | Jefferies | — → Buy | $27 |
| 2021-04-13 | init | SVB Leerink | — → Outperform | $32 |
- BML Capital Management LLC Sells 554,058 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB - MarketBeat Mon, 23 Feb 2026 09
- Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire hu, 19 Feb 2026 14
- Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest shareholders are private equity firms with 39% ownership, individual investors own 22% - Yahoo Finance ue, 16 Dec 2025 08
- Analysts’ Top Healthcare Picks: Context Therapeutics (CNTX), Connect Biopharma Holdings (CNTB) - The Globe and Mail hu, 22 Jan 2026 08
- Connect Biopharma to Terminate ADR Program and List Ordinary Shares on Nasdaq - Nasdaq Mon, 21 Jul 2025 07
- Connect Biopharma stock initiated with Buy rating at BTIG on respiratory drug potential - Investing.com Fri, 31 Oct 2025 07
- Equities Analysts Offer Predictions for CNTB FY2030 Earnings - MarketBeat ue, 27 Jan 2026 08
- 3 Promising Penny Stocks With Market Caps Up To $400M - simplywall.st Wed, 21 Jan 2026 08
- Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Milwaukee Journal Sentinel ue, 18 Nov 2025 12
- Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Wed, 12 Nov 2025 08
- Risk Check: What is the target price for Stellar V Capital Corp stock - 2025 Market WrapUp & Stock Market Timing Techniques - baoquankhu1.vn Mon, 23 Feb 2026 04
- What is HC Wainwright's Forecast for CNTB FY2028 Earnings? - MarketBeat Wed, 28 Jan 2026 08
- Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 - GlobeNewswire Mon, 12 Jan 2026 08
- CNTB Stock Price and Chart — NASDAQ:CNTB - TradingView Fri, 19 Mar 2021 15
- Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Brainstorm Cell Therapeutics (BCLI) - The Globe and Mail Wed, 09 Apr 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -621.39K | -28.20M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -21.79M | -68.34M | -113.78M | -96.93M |
| TotalUnusualItems | 2.88M | -2.96M | -104.43M | |
| TotalUnusualItemsExcludingGoodwill | 2.88M | -2.96M | -104.43M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.63M | -62.11M | -118.09M | -202.27M |
| ReconciledDepreciation | 660.00K | 720.00K | 1.03M | 634.00K |
| EBITDA | -21.79M | -68.34M | -116.74M | -201.36M |
| EBIT | -22.45M | -69.06M | -117.77M | -201.99M |
| NetInterestIncome | 4.45M | 5.22M | 1.52M | 90.00K |
| InterestExpense | 23.00K | 21.00K | 7.00K | |
| InterestIncome | 4.45M | 5.22M | 1.54M | 97.00K |
| NormalizedIncome | -15.63M | -62.11M | -115.75M | -126.03M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.63M | -62.11M | -118.09M | -202.27M |
| TotalExpenses | 48.48M | 69.06M | 116.51M | 96.56M |
| TotalOperatingIncomeAsReported | -22.45M | -69.06M | -119.32M | -98.11M |
| DilutedAverageShares | 55.21M | 55.07M | 54.97M | 52.27M |
| BasicAverageShares | 55.21M | 55.07M | 54.97M | 52.27M |
| DilutedEPS | -0.28 | -1.13 | -2.10 | -3.92 |
| BasicEPS | -0.28 | -1.13 | -2.10 | -3.92 |
| DilutedNIAvailtoComStockholders | -15.63M | -62.11M | -118.09M | -202.27M |
| NetIncomeCommonStockholders | -15.63M | -62.11M | -118.09M | -202.27M |
| NetIncome | -15.63M | -62.11M | -118.09M | -202.27M |
| NetIncomeIncludingNoncontrollingInterests | -15.63M | -62.11M | -118.09M | -202.27M |
| NetIncomeContinuousOperations | -15.63M | -62.11M | -118.09M | -202.27M |
| TaxProvision | 223.00K | 120.00K | 298.00K | 266.00K |
| PretaxIncome | -15.40M | -61.99M | -117.79M | -202.00M |
| OtherIncomeExpense | 2.59M | 1.85M | -2.81M | -105.53M |
| OtherNonOperatingIncomeExpenses | 2.59M | 1.85M | 150.00K | -1.10M |
| SpecialIncomeCharges | 0.00 | -4.70M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 4.70M | 0.00 | |
| GainOnSaleOfSecurity | 2.88M | 1.74M | -104.43M | |
| NetNonOperatingInterestIncomeExpense | 4.45M | 5.22M | 1.52M | 90.00K |
| InterestExpenseNonOperating | 23.00K | 21.00K | 7.00K | |
| InterestIncomeNonOperating | 4.45M | 5.22M | 1.54M | 97.00K |
| OperatingIncome | -22.45M | -69.06M | -116.51M | -96.56M |
| OperatingExpense | 48.48M | 69.06M | 116.51M | 96.56M |
| OtherOperatingExpenses | -1.58M | -929.00K | -2.95M | |
| ResearchAndDevelopment | 29.26M | 53.00M | 96.63M | 80.50M |
| SellingGeneralAndAdministration | 19.23M | 16.05M | 20.81M | 19.01M |
| GeneralAndAdministrativeExpense | 19.23M | 16.05M | 20.81M | 19.01M |
| OtherGandA | 19.23M | 16.05M | 20.81M | 19.01M |
| TotalRevenue | 26.03M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 26.03M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 2.51M | 2.41M | 2.41M | 2.41M |
| OrdinarySharesNumber | 55.35M | 55.10M | 55.04M | 55.08M |
| ShareIssued | 57.86M | 57.51M | 57.45M | 57.48M |
| TotalDebt | 178.00K | 465.00K | 431.00K | 125.00K |
| TangibleBookValue | 92.11M | 101.44M | 154.33M | 268.72M |
| InvestedCapital | 92.17M | 101.50M | 157.49M | 272.26M |
| WorkingCapital | 88.50M | 97.26M | 140.16M | 257.14M |
| NetTangibleAssets | 92.11M | 101.44M | 154.33M | 268.72M |
| CapitalLeaseObligations | 178.00K | 465.00K | 431.00K | 125.00K |
| CommonStockEquity | 92.17M | 101.50M | 157.49M | 272.26M |
| TotalCapitalization | 92.17M | 101.50M | 157.49M | 272.26M |
| TotalEquityGrossMinorityInterest | 92.17M | 101.50M | 157.49M | 272.26M |
| StockholdersEquity | 92.17M | 101.50M | 157.49M | 272.26M |
| OtherEquityInterest | 19.73M | 16.47M | 9.57M | |
| GainsLossesNotAffectingRetainedEarnings | -1.67M | -1.01M | -7.63M | -4.03M |
| OtherEquityAdjustments | -1.67M | -1.01M | -7.63M | -4.03M |
| TreasuryStock | 180.00K | 180.00K | 180.00K | 180.00K |
| RetainedEarnings | -345.36M | -329.73M | -479.84M | -361.75M |
| AdditionalPaidInCapital | 439.36M | 432.40M | 628.66M | 628.64M |
| CapitalStock | 10.00K | 10.00K | 10.00K | 10.00K |
| CommonStock | 10.00K | 10.00K | 10.00K | 10.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 9.12M | 25.88M | 16.52M | 18.80M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 656.00K | 585.00K | 897.00K | 810.00K |
| OtherNonCurrentLiabilities | 632.00K | 405.00K | ||
| NonCurrentDeferredLiabilities | 405.00K | 652.00K | 784.00K | |
| NonCurrentDeferredRevenue | 405.00K | 652.00K | 784.00K | |
| LongTermDebtAndCapitalLeaseObligation | 24.00K | 180.00K | 245.00K | 26.00K |
| LongTermCapitalLeaseObligation | 24.00K | 180.00K | 245.00K | 26.00K |
| CurrentLiabilities | 8.46M | 25.29M | 15.62M | 17.98M |
| CurrentDeferredLiabilities | 164.00K | 13.32M | 0.00 | 0.00 |
| CurrentDeferredRevenue | 164.00K | 13.32M | 0.00 | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 154.00K | 285.00K | 186.00K | 99.00K |
| CurrentCapitalLeaseObligation | 154.00K | 285.00K | 186.00K | 99.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.34M | 2.05M | ||
| PayablesAndAccruedExpenses | 4.80M | 9.64M | 15.44M | 17.89M |
| CurrentAccruedExpenses | 4.46M | 7.43M | 816.00K | 2.32M |
| Payables | 342.00K | 2.21M | 14.62M | 17.89M |
| OtherPayable | 2.35M | 2.69M | 5.15M | |
| AccountsPayable | 342.00K | 2.21M | 11.94M | 12.73M |
| TotalAssets | 101.28M | 127.38M | 174.01M | 291.05M |
| TotalNonCurrentAssets | 4.32M | 4.82M | 18.23M | 15.93M |
| OtherNonCurrentAssets | 33.00K | 24.00K | 34.00K | 2.95M |
| NonCurrentPrepaidAssets | 0.00 | 59.00K | 341.00K | |
| NonCurrentAccountsReceivable | 108.00K | 159.00K | 18.05M | |
| InvestmentsAndAdvances | 0.00 | 9.44M | 0.00 | |
| InvestmentinFinancialAssets | 0.00 | 9.44M | 0.00 | |
| AvailableForSaleSecurities | 9.44M | |||
| GoodwillAndOtherIntangibleAssets | 53.00K | 62.00K | 3.17M | 3.54M |
| OtherIntangibleAssets | 62.00K | 3.17M | 3.54M | |
| NetPPE | 4.24M | 4.74M | 5.38M | 9.44M |
| AccumulatedDepreciation | -2.63M | -2.03M | -1.62M | -898.00K |
| GrossPPE | 6.87M | 6.77M | 7.00M | 10.34M |
| Leases | 830.00K | 626.00K | 762.00K | 733.00K |
| ConstructionInProgress | 0.00 | 0.00 | 3.70M | |
| OtherProperties | 189.00K | 462.00K | 5.49M | 5.55M |
| MachineryFurnitureEquipment | 5.85M | 5.68M | 341.00K | 221.00K |
| BuildingsAndImprovements | 1.19M | 401.00K | 131.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 96.96M | 122.55M | 155.78M | 275.13M |
| OtherCurrentAssets | 53.00K | 54.00K | ||
| PrepaidAssets | 2.15M | 3.85M | 3.13M | 45.14M |
| Receivables | 1.05M | 351.00K | 232.00K | 7.41M |
| OtherReceivables | 178.00K | 232.00K | 7.41M | |
| AccruedInterestReceivable | 262.00K | 351.00K | ||
| AccountsReceivable | 789.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 93.71M | 118.30M | 152.42M | 267.72M |
| OtherShortTermInvestments | 15.48M | 12.64M | 73.41M | 0.00 |
| CashAndCashEquivalents | 78.23M | 105.66M | 79.01M | 267.72M |
| CashEquivalents | 78.32M | 18.37M | 0.00 | |
| CashFinancial | 27.69M | 60.64M | 1.71B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.36M | -47.82M | -105.92M | -91.65M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -566.00K | |
| RepaymentOfDebt | -290.00K | -222.00K | -126.00K | |
| IssuanceOfCapitalStock | 44.00K | 18.00K | 219.99M | |
| CapitalExpenditure | -750.00K | -81.00K | -4.41M | -7.32M |
| IncomeTaxPaidSupplementalData | 111.00K | 120.00K | 462.00K | 0.00 |
| EndCashPosition | 78.23M | 105.66M | 79.01M | 267.72M |
| BeginningCashPosition | 105.66M | 78.95M | 267.72M | 154.80M |
| EffectOfExchangeRateChanges | -595.00K | -568.00K | -858.00K | 224.00K |
| ChangesInCash | -26.84M | 27.28M | -187.85M | 112.69M |
| FinancingCashFlow | 227.00K | 45.00K | -85.00K | 202.22M |
| CashFlowFromContinuingFinancingActivities | 227.00K | 45.00K | -85.00K | 202.22M |
| NetOtherFinancingCharges | -17.11M | |||
| ProceedsFromStockOptionExercised | 227.00K | 45.00K | 119.00K | 34.00K |
| NetCommonStockIssuance | 44.00K | 18.00K | 219.42M | |
| CommonStockPayments | 0.00 | 0.00 | -566.00K | |
| CommonStockIssuance | 44.00K | 18.00K | 219.99M | |
| NetIssuancePaymentsOfDebt | -290.00K | -222.00K | -126.00K | |
| NetLongTermDebtIssuance | -290.00K | -222.00K | -126.00K | |
| LongTermDebtPayments | -290.00K | -222.00K | -126.00K | |
| InvestingCashFlow | -3.45M | 74.98M | -86.24M | -5.21M |
| CashFlowFromContinuingInvestingActivities | -3.45M | 74.98M | -86.24M | -5.21M |
| NetOtherInvestingChanges | -84.00K | |||
| NetInvestmentPurchaseAndSale | -2.70M | 72.12M | -81.84M | 2.12M |
| SaleOfInvestment | 12.75M | 103.14M | 34.23M | 20.08M |
| PurchaseOfInvestment | -15.45M | -31.03M | -116.06M | -17.96M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -48.00K | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -48.00K | |
| NetPPEPurchaseAndSale | -750.00K | 2.86M | -4.41M | -7.28M |
| SaleOfPPE | 0.00 | 2.94M | 0.00 | 0.00 |
| PurchaseOfPPE | -750.00K | -81.00K | -4.41M | -7.28M |
| OperatingCashFlow | -23.61M | -47.74M | -101.52M | -84.32M |
| CashFlowFromContinuingOperatingActivities | -23.61M | -47.74M | -101.52M | -84.32M |
| ChangeInWorkingCapital | -15.49M | 9.85M | 6.46M | 3.58M |
| ChangeInOtherWorkingCapital | -13.17M | 13.55M | ||
| ChangeInOtherCurrentLiabilities | 227.00K | -182.00K | ||
| ChangeInOtherCurrentAssets | 120.00K | 2.70M | -1.36M | |
| ChangeInPayablesAndAccruedExpense | -3.54M | -7.21M | -289.00K | 7.24M |
| ChangeInAccruedExpense | -1.68M | -6.08M | ||
| ChangeInPayable | -1.87M | -1.14M | -289.00K | 7.24M |
| ChangeInAccountPayable | -1.87M | -1.14M | -776.00K | 8.97M |
| ChangeInPrepaidAssets | 1.79M | 3.69M | ||
| ChangeInReceivables | -789.00K | 0.00 | 4.05M | -2.31M |
| ChangesInAccountReceivables | -789.00K | 0.00 | ||
| OtherNonCashItems | -2.01M | -1.33M | 7.00K | |
| StockBasedCompensation | 6.73M | 5.40M | 6.91M | 8.99M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 0.00 | 103.98M | |
| AssetImpairmentCharge | 232.00K | 0.00 | 4.70M | 0.00 |
| AmortizationOfSecurities | -123.00K | -1.70M | ||
| DepreciationAmortizationDepletion | 660.00K | 720.00K | 1.03M | 634.00K |
| DepreciationAndAmortization | 660.00K | 720.00K | 1.03M | 634.00K |
| AmortizationCashFlow | 9.00K | 9.00K | 7.00K | |
| AmortizationOfIntangibles | 9.00K | 9.00K | 7.00K | |
| Depreciation | 979.00K | 1.02M | 627.00K | |
| OperatingGainsLosses | 9.00K | 101.00K | -1.49M | 487.00K |
| GainLossOnInvestmentSecurities | -1.00K | -22.00K | -68.00K | |
| NetForeignCurrencyExchangeGainLoss | -367.00K | -1.47M | 516.00K | |
| GainLossOnSaleOfPPE | 9.00K | 102.00K | 0.00 | 39.00K |
| NetIncomeFromContinuingOperations | -15.63M | -62.11M | -117.79M | -202.00M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CNTB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|